80 results
8-K
PRAX
Praxis Precision Medicines Inc
13 May 24
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
8:18am
firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this information
8-K
EX-1.1
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Other Events
4:30pm
shall have received the opinion and negative assurance letter of Latham & Watkins LLP, counsel for the Company, dated as of such date, in the form … assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., counsel for the Underwriters in connection with the offer and sale of the Offered
424B5
4osuhfcaert3k5i
29 Mar 24
Prospectus supplement for primary offering
4:29pm
424B5
v0ixytqr
27 Mar 24
Prospectus supplement for primary offering
4:49pm
S-3
EX-1.2
i8798m2dvdyt0
5 Mar 24
Shelf registration
9:08am
S-3
8n27p rvkig4ej
5 Mar 24
Shelf registration
9:08am
8-K
cv05cp6x d51
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
8-K
EX-99.2
yktoptuov1qnl71gnu
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
8-K
EX-1.1
aplyvf7lklnir tl
12 Jan 24
Other Events
5:23pm
424B5
vj8tbl9
12 Jan 24
Prospectus supplement for primary offering
5:20pm
424B5
c5045h61l7
10 Jan 24
Prospectus supplement for primary offering
5:28pm
8-K
3zit xwvfjjo8j79
10 Jan 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-1.1
b54bdk98re96cfx89
7 Dec 23
Entry into a Material Definitive Agreement
5:23pm
424B5
py4ymq7
7 Dec 23
Prospectus supplement for primary offering
5:19pm